Aquestive Therapeutics, Inc.

Contributing Author

Recent Articles by Aquestive Therapeutics, Inc.

4 hours	Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly AQST GlobeNewswire
Sep-17	Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm (dibutepinephrine) Sublingual Film AQST GlobeNewswire
Sep-01	Aquestive Therapeutics to Participate in Upcoming September Investor Conferences AQST GlobeNewswire
Aug-11	Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update AQST GlobeNewswire
Aug-10	Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm (dibutepinephrine) Sublingual Film AQST +8.88% GlobeNewswire
Jul-29	Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET AQST GlobeNewswire
Jul-07	Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism AQST GlobeNewswire
May-13	Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update AQST AQST +14.53% GlobeNewswire
May-12	Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree AQST GlobeNewswire
May-06	Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET AQST GlobeNewswire
Mar-30	Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm (dibutepinephrine) Sublingual Film AQST GlobeNewswire
Mar-20	Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer AQST GlobeNewswire
Mar-09	Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4) AQST GlobeNewswire
Mar-04	Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update AQST +6.07% GlobeNewswire
Feb-25	Aquestive Therapeutics to Participate in Upcoming March Investor Conferences AQST GlobeNewswire
Feb-24	Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET AQST GlobeNewswire
Feb-23	Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference AQST GlobeNewswire
Feb-20	Aquestive Therapeutics to Present New Clinical Data on Anaphylm (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting AQST GlobeNewswire
Feb-18	Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer AQST GlobeNewswire
Feb-02	Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm AQST +38.98% GlobeNewswire
Jan-09	Aquestive Therapeutics Announces Regulatory Development for Anaphylm (dibutepinephrine) Sublingual Film and Provides Business Update AQST -37.04% GlobeNewswire
Nov-24	Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference AQST GlobeNewswire
Nov-05	Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update AQST GlobeNewswire
Nov-04	Aquestive Therapeutics Announces Leadership Expansion to Support Growth AQST -6.32% GlobeNewswire
Nov-03	Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler AQST GlobeNewswire
Oct-30	Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting AQST GlobeNewswire
Oct-27	Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET AQST GlobeNewswire
Oct-08	Aquestive Therapeutics Broadens Patent Estate for Anaphylm AQST GlobeNewswire
Sep-04	Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm AQST +28.10% GlobeNewswire
Aug-26	Aquestive Therapeutics to Participate in Upcoming September Investor Conferences AQST GlobeNewswire
Aug-14	Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock AQST GlobeNewswire
Aug-14	Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm (epinephrine) Sublingual Film AQST GlobeNewswire
Aug-11	Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update AQST GlobeNewswire
Aug-04	Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET AQST +5.24% GlobeNewswire
Jul-22	Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer AQST -6.15% GlobeNewswire
Jul-15	Aquestive Therapeutics Provides International Expansion Update for Anaphylm (epinephrine) Sublingual Film AQST GlobeNewswire
Jul-07	Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism AQST GlobeNewswire
Jun-25	Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit AQST GlobeNewswire
Jun-16	Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm for the Treatment of Severe Allergic Reactions AQST GlobeNewswire
May-12	Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update AQST AQST -19.65% GlobeNewswire
May-05	Aquestive Therapeutics to Participate in Citizens Life Sciences Conference AQST -5.67% GlobeNewswire

Aquestive Therapeutics, Inc.

Recent Articles by Aquestive Therapeutics, Inc.

Upgrade your Finviz experience